Related Experiment Video
Updated: Feb 25, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
A brain proteomic investigation of rapamycin effects in the Tsc1+/- mouse model
Hendrik Wesseling1, Ype Elgersma2, Sabine Bahn1,2
1Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QT UK.
Background:
Tuberous sclerosis complex (TSC) is a rare monogenic disorder characterized by benign tumors in multiple organs as well as a high prevalence of epilepsy, intellectual disability and autism. TSC is caused by inactivating mutations in the TSC1 or TSC2 genes. Heterozygocity induces hyperactivation of mTOR which can be inhibited by mTOR inhibitors, such as rapamycin, which have proven efficacy in the treatment of TSC-associated symptoms. The aim of the present study was (1) to identify molecular changes associated with social and cognitive deficits in the brain tissue of Tsc1+/- mice and (2) to investigate the molecular effects of rapamycin treatment, which has been shown to ameliorate genotype-related behavioural deficits.
Methods:
Molecular alterations in the frontal cortex and hippocampus of Tsc1+/- and control mice, with or without rapamycin treatment, were investigated. A quantitative mass spectrometry-based shotgun proteomic approach (LC-MSE) was employed as an unbiased method to detect changes in protein levels. Changes identified in the initial profiling stage were validated using selected reaction monitoring (SRM). Protein Set Enrichment Analysis was employed to identify dysregulated pathways.
Results:
LC-MSE analysis of Tsc1+/- mice and controls (n = 30) identified 51 proteins changed in frontal cortex and 108 in the hippocampus. Bioinformatic analysis combined with targeted proteomic validation revealed several dysregulated molecular pathways. Using targeted assays, proteomic alterations in the hippocampus validated the pathways "myelination", "dendrite," and "oxidative stress", an upregulation of ribosomal proteins and the mTOR kinase. LC-MSE analysis was also employed on Tsc1+/- and wildtype mice (n = 34) treated with rapamycin or vehicle. Rapamycin treatment exerted a stronger proteomic effect in Tsc1 mice with significant changes (mainly decreased expression) in 231 and 106 proteins, respectively. The cellular pathways "oxidative stress" and "apoptosis" were found to be affected in Tsc1+/- mice and the cellular compartments "myelin sheet" and "neurofilaments" were affected by rapamycin treatment. Thirty-three proteins which were altered in Tsc1+/- mice were normalized following rapamycin treatment, amongst them oxidative stress related proteins, myelin-specific and ribosomal proteins.
Conclusions:
Molecular changes in the Tsc1+/- mouse brain were more prominent in the hippocampus compared to the frontal cortex. Pathways linked to myelination and oxidative stress response were prominently affected and, at least in part, normalized following rapamycin treatment. The results could aid in the identification of novel drug targets for the treatment of cognitive, social and psychiatric symptoms in autism spectrum disorders. Similar pathways have also been implicated in other psychiatric and neurodegenerative disorders and could imply similar disease processes. Thus, the potential efficacy of mTOR inhibitors warrants further investigation not only for autism spectrum disorders but also for other neuropsychiatric and neurodegenerative diseases.
Insights
Tuberous sclerosis complex (TSC) involves brain changes, with rapamycin treatment normalizing some molecular pathways. This research offers potential new drug targets for autism spectrum disorders and other neurodegenerative diseases.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Tuberous sclerosis complex (TSC) is a rare genetic disorder linked to epilepsy, intellectual disability, and autism.
- It stems from inactivating mutations in TSC1 or TSC2 genes, leading to mTOR hyperactivation.
- mTOR inhibitors, like rapamycin, show promise in treating TSC symptoms.
Purpose of the Study:
- Identify molecular changes in the brain of Tsc1+/- mice associated with social and cognitive deficits.
- Investigate the molecular effects of rapamycin treatment on these deficits.
Main Methods:
- Proteomic analysis using LC-MS^E to detect protein level changes in the frontal cortex and hippocampus of Tsc1+/- mice and controls.
- Validation of identified changes using selected reaction monitoring (SRM).
- Protein Set Enrichment Analysis to identify dysregulated molecular pathways.
Main Results:
- Proteomic analysis revealed significant protein changes in the hippocampus (108 proteins) and frontal cortex (51 proteins) of Tsc1+/- mice.
- Key affected pathways included myelination, dendrite development, and oxidative stress, with upregulation of ribosomal proteins and mTOR kinase.
- Rapamycin treatment significantly altered protein expression in Tsc1+/- mice, affecting pathways like oxidative stress and apoptosis, and normalizing 33 altered proteins, including those related to oxidative stress and myelin.
Conclusions:
- Molecular alterations in Tsc1+/- mouse brains are more pronounced in the hippocampus.
- Myelination and oxidative stress pathways are significantly affected and partially normalized by rapamycin.
- Findings suggest potential therapeutic targets for autism spectrum disorders and other neurodegenerative diseases, warranting further investigation of mTOR inhibitors.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway

